Carolyn F. Sidor
Geen lopende functies
Profiel
Carolyn F.
Sidor served as the Chief Medical Officer & Vice President at CASI Pharmaceuticals, Inc. from 2001 to 2012.
She then worked as the Chief Medical Officer & Senior Vice President at Kolltan Pharmaceuticals, Inc. from 2013 to 2014.
Prior to that, she was the Vice President-Scientific & Medical Development at Cato Research LLC.
Sidor holds a doctorate from Thomas Jefferson University, an undergraduate degree from SUNY College of Environmental Science, and an MBA from the University of Delaware.
Eerdere bekende functies van Carolyn F. Sidor
| Bedrijven | Functie | Einde |
|---|---|---|
CASI Pharmaceuticals, Inc. /Old/
 CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Hoofd Techniek/Wetenschap/O&O | 23-05-2012 |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Hoofd Techniek/Wetenschap/O&O | - |
Cato Research LLC
 Cato Research LLC Miscellaneous Commercial ServicesCommercial Services Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Carolyn F. Sidor
| Thomas Jefferson University | Doctorate Degree |
| University of Delaware | Masters Business Admin |
| SUNY College of Environmental Science | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Health Technology |
Cato Research LLC
Cato Research LLC Miscellaneous Commercial ServicesCommercial Services Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC. | Commercial Services |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
